Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.

Date publication

octobre 2019

Journal

Clinics and research in hepatology and gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Mme POZET Astrid

Tous les auteurs :
Pointet AL, Tougeron D, Pernot S, Pozet A, Béchade D, Trouilloud I, Lourenco N, Hautefeuille V, Locher C, Williet N, Desrame J, Artru P, Soularue E, Le Roy B, Taieb J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31607641

Résumé

A combination of nab-paclitaxel plus gemcitabine (N+G) has recently become a standard first-line treatment in patients with metastatic pancreatic adenocarcinoma (MPA), but there are currently no published data concerning second-line treatment after N+G. The aim of this study was to evaluate the survival outcomes and tolerability of three usual fluoropyrimidine-based regimens FOLFOX, FOLFIRI and FOLFIRINOX after N+G failure in MPA patients.

Mots clés

FOLFIRI, FOLFIRINOX, FOLFOX, Metastatic pancreatic cancer, Nab-paclitaxel plus gemcitabine, Second-line chemotherapy

Référence

Clin Res Hepatol Gastroenterol. 2019 Oct 10;: